STAT May 29, 2024
John Wilkerson

WASHINGTON — Clinical trials that the National Institutes of Health funds often enroll fewer Black patients and other underrepresented racial groups than they plan to, according to a study of 30 NIH-funded trials sampled by the HHS Office of Inspector General.

Policymakers want to get researchers to enroll a racially representative sample of patients in clinical trials that test whether products work and are safe. But researchers often fail to do so.

The OIG findings are in line with other studies from outside the government, according to William Fitzsimmons, a founder of the CARER Group, which is pushing to improve trial diversity. However, those studies looked at clinical trials funded by drug and medical device companies.

“One would assume that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Equity/SDOH, Govt Agencies, Healthcare System, OIG, Patient / Consumer, Survey / Study, Trends
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
Charting the road to operational success in clinical trials
Why Former FDA & Verily Exec Amy Abernethy Is Launching a New Venture
AI's Drug Revolution, Part 1: Faster Trials and Approvals
How do drugs like Ozempic work? And why are they on trial?

Share This Article